---
schema_version: "secwatch.filing_event.v1"
accession: "0001854270-23-000125"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:32:04.606729+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Senti Bio Q3 net loss $14.9M; cash $39.4M; Celest partnership up to $156M

## Summary
- Net loss $14.9M ($0.34/share) includes non-recurring $21.7M gain and $25.7M impairment from GeneFab transaction.
- Cash and short-term investments $39.4M; expects to fund operations into Q4 2024.
- SENTI-202 IND on track for clearance Q4 2023; Phase 1 trial for AML expected to start early 2024.
- Celest collaboration for SENTI-301A: up to $156M milestones plus tiered royalties; first patient H1 2024 in China.
- GeneFab transaction: $37.8M total consideration; $18.9M at closing, $18.9M in installments 2024-2025.

## SEC filing metadata
- accession: 0001854270-23-000125
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000185427023000125/0001854270-23-000125-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000185427023000125/snti-20231113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001854270-23-000125
- JSON: https://secwatch.observer/filing/0001854270-23-000125.json
- Plain text: https://secwatch.observer/filing/0001854270-23-000125.txt

## Key facts
- Earnings Releases
  Senti Biosciences, Inc. reported third quarter of 2023 results: net income 14.9, EPS 0.34.
  - Period: third quarter of 2023
  - Net income: 14.9
  - EPS: 0.34
  - Result: reported results
  source text: Net loss was $14.9 million, or $0.34 per basic and diluted share, for the quarter ended September 30, 2023, which included a non-recurring $21.7 million gain from discontinued operations, as well as a non-recurring $25.7 million impairment for leasehold improvements, both related to the GeneFab transaction.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000185427023000125/0001854270-23-000125-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.